Product

LAE001/prednisone + afuresertib

Aliases

Phase I and Phase II: LAE001/prednisone + afuresertib, Phase II: Afuresertib

1 clinical trial

1 indication

Indication

Metastatic Castration-resistant Prostate Cancer

Clinical trial

A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment

Status: Active (not recruiting), Estimated PCD: 2023-12-27